VistaGen Therapeutics, Inc. — Form 10-Q Summary
Business and period: Development-stage biotechnology company focused on stem-cell-based drug rescue and toxicity screening, and AV-101, an investigational treatment for neuropathic pain. This fiscal second-quarter report covers the three and six months ended September 30, 2012; the balance-sheet comparison is to March 31, 2012.
Financial results and position
| Metric | Three months ended Sept. 30, 2012 | Six months ended Sept. 30, 2012 | Comparable 2011 period |
|---|---|---|---|
| Revenue | $0 | $200,400 | $316,300; $870,900 |
| Operating expenses | $1.682 million | $3.604 million | $2.122 million; $4.277 million |
| Net loss | $1.956 million | $3.782 million | $2.256 million; $4.667 million |
| Basic and diluted loss per share | $(0.12) | $(0.22) | $(0.15); $(0.35) |
| Net cash used in operating activities | Not provided for quarter | $1.531 million | $1.789 million for six months |
Revenue was grant and subcontract-related, not product sales. Six-month revenue declined 77% year over year, while net loss narrowed about 19%. Operating expenses fell about 16%; lower interest expense contributed to the lower net loss. No meaningful operating margin is available given the lack of recurring commercial revenue.
At September 30, cash was $13,400, versus $81,000 at March 31. Current assets were $328,400 and current liabilities $2.945 million, a working-capital deficit of approximately $2.617 million. Total liabilities were $6.882 million, compared with $6.047 million at March 31; stockholders’ deficit was $6.458 million. Debt includes $1.25 million of new 10% senior secured Platinum notes and substantial vendor and professional-services obligations. The filing does not present a single aggregate gross-debt figure.
Changes, outlook and risks
- AV-101 was in Phase 1b development; the NIH grant supporting it expired June 30, 2012 and was not renewed. The company reported no grant revenue in the September quarter.
- Management estimated cash expenditures of $4 million to $6 million over the next 12 months and stated that available cash, including subsequent note proceeds, would not fund operations for that period. The company depends on further financing, collaborations, licensing revenue and grants; it warned that failure to obtain funding could require reduced or discontinued research and could jeopardize its ability to continue as a going concern.
- After quarter-end, Platinum purchased $1 million of a planned $2 million in additional notes. The remaining $1 million was conditional on the company securing at least $850,000 in additional financing. The notes bear 10% interest and are secured; associated warrants and a potential Series A preferred-stock exchange could materially dilute common shareholders.
- Past-due obligations were restructured after quarter-end, including amounts owed to Cato Research and University Health Network through notes payable in restricted shares and related warrants. The UHN research agreement also set a $309,000 budget for October 2012–September 2013.
- Unusual items included a $440,700 non-cash warrant-modification charge in the six-month period and substantial warrant-related discounts on restructured Morrison & Foerster debt. The February 2012 notes’ registration statement had not been filed; a $20,700 registration-rights liability was recorded.
- Management cited financing availability, clinical and preclinical results, regulatory requirements and competition as key uncertainties. It reported effective disclosure controls and no ongoing legal proceedings.
Key facts investors should verify
- Whether the required additional financing was completed and the conditional Platinum note tranches were issued.
- Cash runway, subsequent cash use, and the timing and terms of further financing.
- AV-101 Phase 1b results and any replacement funding after NIH grant expiration.
- Debt maturities, payment defaults or modifications, and the potential dilution from outstanding and subsequently issued warrants and preferred shares.
- Whether the registration-rights filing obligation was met and whether further penalties accrued.